EMA sets clock ticking for life sciences companies to get their data in order

The European Medicines Agency (EMA) has published IDMP data standardsthat will drive change and innovation in the life sciences sector.

Remco Munnik, Associate Director at Life Sciences consultancy, Iperion, has been working with the group creating the EU IDMP Implementation Guide version 2.0 (EU IG). Iperion will revealthe implications of the data standards for the life sciences sector in a webinar on 1 March.

The EU IG, covering the submission of data on medicinal products, sets out the implementation requirements of the ISO IDMP standards in the EU.The launch of the EU IG sets the clock ticking for life sciences companies doing business in the EU to start getting their data in order and processes in place. Additionally, the new Target Operating Model (TOM) will mean that existing processes need to be amended to collect more data and at an earlier point in the current process.

In Iperion’s view, the new data standards provide the opportunity to link the regulatory world with the supply chain world. Until now, the supply chain, regulatory, pharmacovigilance, and clinical functions might all use different names for the same products and active substance(s). Now these different worlds will be able to speak the same language, sharing data and terminology that will simplify manufacturing, supply chain and patient information data sharing.

Compliance with ISO IDMP will provide an opportunity as well as a being a regulatory exercise. Standardised data will drive more efficient processes. Beyond that, standardisation will support fresh and innovative ways of sharing data and automation across the regulatory and supply chain divide. Life sciences companies will be able to use this to gain competitive advantage.

As the world watches the fast roll-out of the coronavirus vaccine, unnecessary delay is no longer acceptable. In parallel with the launch of the EU IG version 2.0, the sector’s response to the pandemic has further highlighted the pressing need for data standards – so that data may be shared to report on supply chain issues, which vaccines are administered to which patients, adverse events and for patient information.

Munnik said: “At Iperion we are proud to have worked closely with the regulator to help steer the development of these major standards and we are delighted to see IDMP version 2 come to fruition right on schedule.”

Iperion is running a webinar on 1March at 4pm CET / 10am ET to provide the inside track on the implications of the new data standards. Register for the webinar here.

Image credit: Christine Sandu

Suggested Reading

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free